

Haemolytic transfusion reaction

Condition for which IVIg use is in exceptional circumstances only

Specific Conditions

- Haemolytic transfusion reaction

Level of Evidence

Insufficient data (Category 4a)

Intravenous immunoglobulin (IVIg) may be considered in the management or prevention of severe haemolytic transfusion reaction not responding to other interventions (e.g. corticosteroids).

Refer to the current product information sheet for further information.

The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.

Bibliography

Win, N, Madan, B, Gale, R, et al 2005, 'Intravenous immunoglobulin given to lymphoma patients with recurrent haemolytic transfusion reactions after transfusion of compatible blood', *Hematology*, vol. 10, no. 5, pp. 375–8.

Generated on: 31 March 2019